United Therapeutics Corporation
UTHR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $799,500 | $798,600 | $794,400 | $735,900 |
| % Growth | 0.1% | 0.5% | 7.9% | – |
| Cost of Goods Sold | $100,900 | $87,600 | $92,500 | $75,900 |
| Gross Profit | $698,600 | $711,000 | $701,900 | $660,000 |
| % Margin | 87.4% | 89% | 88.4% | 89.7% |
| R&D Expenses | $127,500 | $134,000 | $149,000 | $133,800 |
| G&A Expenses | $0 | $159,800 | $143,500 | $135,500 |
| SG&A Expenses | $182,600 | $190,800 | $170,100 | $162,500 |
| Sales & Mktg Exp. | $0 | $31,000 | $26,600 | $27,000 |
| Other Operating Expenses | $0 | $21,700 | $0 | $6,000 |
| Operating Expenses | $310,100 | $346,500 | $319,100 | $302,300 |
| Operating Income | $388,500 | $364,500 | $382,800 | $357,700 |
| % Margin | 48.6% | 45.6% | 48.2% | 48.6% |
| Other Income/Exp. Net | $49,500 | $43,900 | $40,700 | $38,800 |
| Pre-Tax Income | $438,000 | $408,400 | $423,500 | $396,500 |
| Tax Expense | $99,300 | $98,900 | $101,300 | $95,200 |
| Net Income | $338,700 | $309,500 | $322,200 | $301,300 |
| % Margin | 42.4% | 38.8% | 40.6% | 40.9% |
| EPS | 7.73 | 6.86 | 7.18 | 6.74 |
| % Growth | 12.7% | -4.5% | 6.5% | – |
| EPS Diluted | 7.16 | 6.41 | 6.63 | 6.19 |
| Weighted Avg Shares Out | 43,800 | 45,100 | 44,900 | 45,200 |
| Weighted Avg Shares Out Dil | 47,300 | 48,300 | 48,600 | 48,700 |
| Supplemental Information | – | – | – | – |
| Interest Income | $46,400 | $51,300 | $51,100 | $49,300 |
| Interest Expense | $3,000 | $7,300 | $6,100 | $7,900 |
| Depreciation & Amortization | $21,900 | $21,100 | -$34,600 | $19,700 |
| EBITDA | $462,900 | $436,800 | $382,800 | $424,100 |
| % Margin | 57.9% | 54.7% | 48.2% | 57.6% |